SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.293
AS - Asia 4.805
EU - Europa 3.937
SA - Sud America 844
AF - Africa 101
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 7
Totale 17.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.063
SG - Singapore 2.240
IT - Italia 1.453
CN - Cina 1.153
PL - Polonia 765
BR - Brasile 708
DE - Germania 533
HK - Hong Kong 524
VN - Vietnam 350
GB - Regno Unito 244
FI - Finlandia 178
RU - Federazione Russa 153
ID - Indonesia 134
UA - Ucraina 132
SE - Svezia 126
MX - Messico 105
CA - Canada 99
IN - India 91
TR - Turchia 90
NL - Olanda 75
FR - Francia 74
AR - Argentina 61
AT - Austria 50
BD - Bangladesh 49
ES - Italia 37
ZA - Sudafrica 36
JP - Giappone 34
LT - Lituania 29
IQ - Iraq 28
BE - Belgio 25
EC - Ecuador 16
CO - Colombia 15
KE - Kenya 15
CZ - Repubblica Ceca 13
AE - Emirati Arabi Uniti 12
CL - Cile 12
MA - Marocco 12
IE - Irlanda 11
PY - Paraguay 10
TH - Thailandia 10
AU - Australia 9
CH - Svizzera 9
CM - Camerun 9
PE - Perù 9
UZ - Uzbekistan 9
EG - Egitto 8
KR - Corea 8
MY - Malesia 8
PK - Pakistan 8
VE - Venezuela 8
TN - Tunisia 7
IL - Israele 6
SA - Arabia Saudita 6
DO - Repubblica Dominicana 5
EU - Europa 5
HN - Honduras 5
KZ - Kazakistan 5
PH - Filippine 5
AL - Albania 4
BG - Bulgaria 4
DZ - Algeria 4
GE - Georgia 4
IR - Iran 4
NO - Norvegia 4
AZ - Azerbaigian 3
DK - Danimarca 3
JM - Giamaica 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
PS - Palestinian Territory 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BY - Bielorussia 2
GT - Guatemala 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
SN - Senegal 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TG - Togo 2
UY - Uruguay 2
AP - ???statistics.table.value.countryCode.AP??? 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
DM - Dominica 1
GA - Gabon 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KI - Kiribati 1
Totale 16.986
Salva come PNG Salva come JPEG
Città #
Singapore 1.217
Ashburn 1.176
Warsaw 758
Beijing 614
Fairfield 588
Santa Clara 585
Hong Kong 523
Chandler 348
Woodbridge 309
Houston 249
Munich 248
Wilmington 237
Seattle 230
Los Angeles 182
Cambridge 176
Princeton 154
Dallas 144
Ferrara 138
Ho Chi Minh City 121
Jakarta 115
Ann Arbor 111
Milan 108
New York 105
Jacksonville 103
Helsinki 86
Rome 79
Mexico City 76
Shanghai 70
Dong Ket 69
San Diego 68
London 67
São Paulo 65
Turku 64
Hanoi 63
Bremen 59
Nuremberg 57
Bologna 54
Brooklyn 49
Izmir 47
Washington 43
Chicago 41
Boardman 39
Falls Church 37
Nanjing 37
Stockholm 35
Frankfurt am Main 34
Tokyo 33
Denver 32
Verona 32
Atlanta 31
Chennai 31
Orem 31
Redwood City 31
Boston 29
Montreal 29
Buffalo 28
Toronto 28
Dearborn 27
Falkenstein 27
Johannesburg 27
The Dalles 27
Addison 26
Poplar 26
Rio de Janeiro 26
San Francisco 25
Moscow 24
Brussels 23
Phoenix 22
Santa Maria Di Sala 22
Amsterdam 21
Manchester 21
Hefei 20
Tianjin 20
Naples 19
Vienna 19
Belo Horizonte 18
San Jose 16
Charlotte 15
Da Nang 15
Mountain View 15
Norwalk 15
San Mateo 15
Ankara 14
Council Bluffs 14
Padova 14
Nairobi 13
Haiphong 12
Augusta 11
Brasília 11
Portsmouth 11
Curitiba 10
Mumbai 10
Nanchang 10
Porto Alegre 10
Shenyang 10
Baghdad 9
Birmingham 9
Columbus 9
Dhaka 9
Fortaleza 9
Totale 10.839
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 671
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 315
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 239
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 210
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 197
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 188
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 188
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 178
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 164
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 158
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 156
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 156
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 153
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 152
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 152
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 151
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 151
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 150
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 148
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 145
Factors that influence HCV related liver disease severity in Italian patients in care: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) HCV cohort study". 144
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 143
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 141
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 138
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 138
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 137
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 136
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 136
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 135
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 134
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 133
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 132
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 132
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 131
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 128
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI 128
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 127
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 127
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 126
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 126
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 125
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 124
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 124
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 123
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 122
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 122
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 121
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 119
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 118
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 118
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 117
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 117
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 113
Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study 113
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 113
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 112
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 112
Multidrug Resistant Bacterial Co-Infections in Critically Ill Patients with COVID-19: A Review after Three Years of Pandemic 110
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 110
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort 110
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 110
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 110
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 109
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 109
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 109
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies 109
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 109
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 107
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: Data from the ICONA foundation study group, years 1997-2013 107
Associations between immune depression and cardiovascular events in HIV infection 106
null 106
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 105
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 105
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 104
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 104
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 103
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 101
Antiretroviral Therapy Partially Restores Phenotypic and Metabolic Immunosenescence Features of T Cells in Hiv Infected Individuals 99
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 99
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 99
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 98
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 98
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 97
Time to undetectable viral load achievement after art start and risk of mortality. 97
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 95
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 95
Endocrinological aspects of hypophosphatemia in HIV infection. Pilot study on Vitamin D supplementation: an observational study 95
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 95
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 94
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 94
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 94
Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 93
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 93
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 92
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 92
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 92
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 92
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 91
Evolution and reversibility of renal function after switch from TDF to TAF regimens 91
HIV-associated TB in a low burden country: is screening for latent TB still needed? 90
Totale 13.025
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.927
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.061
Totale 103.988
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.422 0 0 0 0 0 303 224 211 124 310 89 161
2021/20221.086 74 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20254.195 101 88 350 163 469 482 155 167 683 550 540 447
2025/20265.492 1.035 396 811 1.120 1.652 478 0 0 0 0 0 0
Totale 17.408